Today, there are many aids to help the smokers to quit smoking. CHANTIX is a prescription medicine that helps smokers to stop smoking. Most people try to quit smoking for 6-9 times in their life but they just can’t avoid the temptations of smoking. With the help of CHANTIX you can permanently quit smoking. It uses two-part approach by addressing the physical side of quitting smoking and giving step by step support to help them quit smoking. Unlike the other quit smoking products, CHANTIX targets nicotine receptors in brain and blocks the nicotine to reach them. It works by stopping the effects of nicotine in the body that reduce the pleasure of smoking.

However, there are sides effects come with the use of CHANTIX. The most common side effects are nausea, sleep problems, constipation, gas, and vomiting. If you experience the symptoms after consuming CHANTIX, you should immediately go to your doctor.

Now, quitting from smoking is no longer impossible because soon you can buy CHANTIX anti smoking pills. This pill had been approved by the US FDA to be sold in the market. This pill is the latest technology in reducing the number of smokers and also helping smokers that want to quitting from the cigarette. This pill has several advantages that can help you quitting from smoking. First, it reduces the addiction, and the second, it can make the smoking has less pleasure.

Unfortunately, some psychiatrics organizations has questioned the CHANTIX anti smoking because in some cases it can cause depression. For further info about this thing you can browse internet to get related articles. It all your choice; you want to quit smoking by your own willing or you need drugs to help you do it.

Chantix is giving their patients some kind a pill that they said that it will makes the people will do not have any desires to smoke again. The pills do not contain nicotine too so that the people who addicted to the smoke will not addicted to the pills either. But the latest issue about this Chantix is not good news for everybody. Well, the issue is telling that the pills given by Chantix are creating hallucinations to the people who consume the pills and the patients are doing things that indicate the symptoms of mental disorders.

There is also one disturbing case that happen to the Texas musician who killed someone because of the hallucinations that caused by the pills given by the Chantix. Well, this case is proving that the people must be very careful in taking medical treatment. No matter what the benefits that the people can get, the people are supposed to gain information related to the things that they were doing as much as possible.

The spots run 90 seconds–30 seconds more than the ones Pfizer (nyse: PFE – news – people ) ran for just four months last year–and hew to the same narrative as the old one, using a race between a tortoise and a Belgian hare to dramatize the fact that quitting smoking that favors the slow and steady–and that Chantix can help.

Side effect information takes up 41 seconds of the advertisement, with about 20 seconds devoted to a warning that patients taking Chantix should stop taking it if they experience agitation, suicidal thoughts or suicidal behavior. Pfizer says the role of Chantix in those symptoms is “not known.”

“Some people think the drug has been withdrawn from the market,” says Veronique Cardon, team leader of U.S. marketing for Chantix. “More importantly, a lot of people haven’t heard of Chantix yet.”

The new campaign shows how pharmaceutical companies are trying to adapt the marketing of their products to a climate of hair-trigger concern over drug safety. But Pfizer faces other hurdles in launching Chantix, too. Its own communications to Wall Street before Chantix went on sale described the anti-smoking market as prone to dramatic sales spikes and stomach-heaving drops.

The drug’s success is particularly important as it tries to match the success of older medications like Lipitor, which loses patent protection in just three years. Pfizer shares have fallen 25% in 12 months.

Safety controversies only make that tougher. When ads are pulled because of new and serious side effects, some reappear in a longer form with more detail about the new risks, says Ruth Day, director of the Medical Cognition Laboratory at Duke University. This also happened with ads for Celebrex (also a Pfizer drug) after it was linked to an elevated risk of heart disease.

By Salynn Boyles
WebMD Health News
Reviewed by Louise Chang, MD

Oct. 1, 2009 — The antismoking drug Chantix has been linked to suicide and suicidal thoughts, but a new study shows that if such a risk exists it is likely to be very small.

Researchers from the U.K.’s drug regulatory agency and the University of Bristol compared the incidence of suicide and self-harm among smokers taking Chantix to that of smokers using the drug Zyban or nicotine-replacement products to help them give up cigarettes.

Last July, the FDA announced it would require labeling for Chantix and Zyban to include its strongest safety message, warning that people taking the drugs should be closely watched for signs of suicidal thoughts, hostility, and depressed mood in users.

At a news briefing, an FDA official said 98 suicides and 188 suicide attempts had been reported among people taking Chantix since the drug was approved for sale in the U.S. in 2006.

Fourteen suicides and 17 suicide attempts had been reported in users of Zyban, which contains the same active ingredient as the antidepressant Wellbutrin.

Using data from a medical registry with roughly 3.6 million people living in the U.K., epidemiologist David Gunnell, PhD, and colleagues identified 80,660 adults who were prescribed smoking-cessation products between September 2006 and May 2008.

About three-quarters of the prescriptions were for nicotine-replacement therapies, including patches, inhalers, gum, tablets, or lozenges. Slightly fewer than 11,000 prescriptions were for Chantix and around 6,400 were for Zyban.

Using electronic medical records, the researchers searched for evidence of fatal and non-fatal self-harm, suicidal thoughts, and depression over the period in which the treatments were used up until three months after the last prescription was filled.

After controlling for known risk factors for self-harm and depression, the researchers found no clear evidence of an increased risk of self-harm, suicidal thoughts, or depression in Chantix users or users of any of the other products.

“This is the first study to look at this question in detail, and the results are largely reassuring,” Gunnell tells WebMD. “Our best estimate is that if there is an increase in the risk for fatal and non-fatal self-harm associated with [Chantix] the risk is likely to be very small.”

Gunnell says larger studies are needed to further quantify the risk. “Any such risk has to be balanced against the risks associated with continuing to smoke.”

The study was paid for by the U.K.’s drug regulatory group, the Medicines and Healthcare Products Regulatory Agency (MHRA).

It was published today in the journal BMJ Online First.

In a statement issued Thursday afternoon, a spokeswoman for Pfizer Inc., which markets Chantix in the U.S., told WebMD the company considers the overall risk-benefit profile of the drug to be ‘favorable.”

“Given the significant public health risks of smoking, Chantix is an important treatment option for adults who want to quit smoking,” Pfizer’s Sally Beatty noted.

She added that the company is conducting clinical trials of the drug in patients with psychiatric disorders as well as other patient populations.